Abstract
Comparative analyses of the immunogenicity and reactogenicity of homologous and heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we analyze the humoral and cellular immune response following heterologous and homologous vaccination strategies in a convenience cohort of 331 healthy individuals. All regimens induce immunity to the vaccine antigen. Immunity after vaccination with ChAdOx1-nCoV-19 followed by either BNT162b2 (n = 66) or mRNA-1273 (n = 101) is equivalent to or more pronounced than homologous mRNA-regimens (n = 43 BNT162b2, n = 59 mRNA-1273) or homologous ChAdOx1-nCoV-19 vaccination (n = 62). We note highest levels of spike-specific CD8 T-cells following both heterologous regimens. Among mRNA-containing combinations, spike-specific CD4 T-cell levels in regimens including mRNA-1273 are higher than respective combinations with BNT162b2. Polyfunctional T-cell levels are highest in regimens based on ChAdOx1-nCoV-19-priming. All five regimens are well tolerated with most pronounced reactogenicity upon ChAdOx1-nCoV-19-priming, and ChAdOx1-nCoV-19/mRNA-1273-boosting. In conclusion, we present comparative analyses of immunogenicity and reactogenicity for heterologous vector/mRNA-boosting and homologous mRNA-regimens.
【초록키워드】 SARS-CoV-2, Vaccine, vaccination, reactogenicity, Immunity, Cellular immune response, mRNA-1273, Antigen, BNT162b2, Cohort, T-cell, homologous, Heterologous, Combination, Analysis, Vaccination strategy, humoral, regimen, Comparative, healthy individuals, combinations, regimens, ChAdOx1-nCoV-19, FIVE, CD4 T-cell, highest, induce, the vaccine, CD8 T-cell, 【제목키워드】 COVID-19 vaccine, reactogenicity, BNT162b2, homologous, Heterologous, regimen, Comparative,